Serina Therapeutics Advances Once-Weekly Injectable for Tardive Dyskinesia

Serina Therapeutics Advances Once-Weekly Injectable for Tardive Dyskinesia

By, Admin 1 August 2025

Serina Therapeutics, a clinical-stage biotech firm, has announced the advancement of SER-270, a once-weekly injectable treatment for tardive dyskinesia (TD). The novel drug leverages Serina’s proprietary POZ polymer technology, offering an alternative to current oral VMAT2 inhibitors.

What is SER-270?

  • SER-270 is a POZ-conjugated VMAT2 inhibitor.
  • Designed for subcutaneous weekly administration.
  • Targets patients struggling with daily medication adherence, especially those on long-acting injectable (LAI) antipsychotics.

Tardive dyskinesia is a serious, underdiagnosed movement disorder linked to long-term antipsychotic use. Most affected individuals have chronic psychiatric conditions like schizophrenia or bipolar disorder.

  • <30% of TD patients in the U.S. are diagnosed.
  • Fewer than half of those receive treatment.
  • The TD drug market surpassed $3.7B in 2024 and is expected to grow to $5.4B by 2030.

SER-270 Targets Key Gaps in Current TD Care

POZ-VMAT2i offers a differentiated solution:

  • Once-weekly injection: Ideal for patients non-compliant with daily pills.
  • Better fit for institutions: Eases logistical challenges for caregivers.
  • Non-oral: Supports patients with dysphagia, including the elderly and neurologically impaired.

Expansion Potential: Huntington’s Disease

Serina plans to evaluate SER-270 for chorea in Huntington’s disease. Many patients in this population struggle with swallowing, making injectables more practical than oral drugs.

Leadership Perspective

“POZ-VMAT2i solves real-world barriers—non-compliance, institutional care, and swallowing issues. It’s about expanding access and improving lives.”

  • Steve Ledger, CEO of Serina Therapeutics

About Serina Therapeutics

Serina is developing a pipeline of drug candidates using its POZ Platform to improve delivery, dosing, and patient adherence, primarily for neurological diseases and movement disorders.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!